Management of head and neck cancer in elderly patients

Drugs and Aging

Volumn 26, Issue 7, 2009, Pages 571-583

  Lalami, Yassine ^a   De Castro Jr , Gilberto ^b   Bernard Marty, Chantal ^a   Awada, Ahmad ^a  

^a JULES BORDET INSTITUTE   (Belgium)

^b Centro Paulista de Oncologia and Oncoclinicas do Brasil Group   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CARBOPLATIN; CEDIRANIB; CETUXIMAB; CISPLATIN; CYTOTOXIC AGENT; DESATINIB; DEXAMETHASONE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUOROURACIL; GEFITINIB; HEMOPOIETIC GROWTH FACTOR; IXABEPILONE; LAPATINIB; METHOTREXATE; PACLITAXEL; PEMETREXED; PROTECTIVE AGENT; SODIUM THIOSULFATE; TAXANE DERIVATIVE; UNCLASSIFIED DRUG; VANDETANIB;

ACUTE TOXICITY; ADVANCED CANCER; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARDIOTOXICITY; CELL PROTECTION; CHEMOTHERAPY INDUCED EMESIS; CHRONIC TOXICITY; CLINICAL ASSESSMENT; CLINICAL TRIAL; COGNITION; COMORBIDITY; DERMATITIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG HYPERSENSITIVITY; ELDERLY CARE; FEBRILE NEUTROPENIA; FUNCTIONAL STATUS; GERIATRIC ASSESSMENT; GERIATRIC PATIENT; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HEARING IMPAIRMENT; HUMAN; HYPOKALEMIA; HYPOMAGNESEMIA; LIVER DYSFUNCTION; METASTASIS; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NAUSEA; NECK DISSECTION; NEPHROTOXICITY; NEUTROPENIA; NUTRITIONAL SUPPORT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION SAFETY; RADIATION SICKNESS; RECURRENT CANCER; REVIEW; SEPSIS; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; STOMATITIS; THROMBOCYTOPENIA; TRANSAMINITIS; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR BLEEDING;

AGED; ANTINEOPLASTIC AGENTS; COMBINED MODALITY THERAPY; HEAD AND NECK NEOPLASMS; HUMANS;

EID: 70349146231     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.2165/11316340-000000000-00000     Document Type: Review

References (90)

1. Bernardi D, Barzan L, Franchin G, et al. Treatment of head and neck cancer in elderly patients: State of the art and guidelines. Crit Rev Oncol Hematol 2005; 53: 71-80
2. Genden EM, Rinaldo A, Shara AR, et al. Treatment considerations for head and neck cancer in the elderly. J Laryngol Otol 2005; 119: 169-174
3. Alho O-P, Hannula K, Luokkala A, et al. Differential prognostic impact of comorbidity in head and neck cancer. Head Neck 2007; 29: 913-918
4. Yung KC, Piccirillo JF. The incidence and impact of comorbidity diagnosed after the onset of head and neck cancer. Arch Otolaryngol Head Neck Surg 2008; 134: 1045-1049
5. Reid BC, Alberg AJ, Klassen AC, et al. Comorbidity and survival of elderly head and neck cancer patients. Cancer 2001; 92: 2109-2116
6. Allareddy V, Konety BR. Characteristics of patients and predictors of in-hospital mortality after hospitalization for head and neck cancers. Cancer 2006; 106: 2382-2388
7. Derks W, de Leeuw JR, Hordijk GJ, et al. Reasons for nonstandard treatment in elderly patients with advanced head and neck cancer. Eur Arch Otorhinolaryngol 2005; 262: 21-26
8. Sesterhenn AM, Teymoortash A, Folz BJ, et al. Head and neck cancer in the elderly: A cohort study in 40 patients. Acta Oncol 2005; 44: 59-64
9. Olmi P, Ausili-Cefaro G. Radiotherapy in the elderly: A multicentric prospective study on 2060 patients referred to 37 Italian radiation therapy centers. Rays 1997; 22 (1 Suppl.): 53-56
10. Sarini J, Fournier C, Lefebvre JL, et al. Head and neck squamous cell carcinoma in elderly patients: A long-term retrospective review of 273 cases. Arch Otolaryngol Head Neck Surg 2001; 127: 1089-1092
11. Bhattacharyya N. A matched survival analysis for squamous cell carcinoma of the head and neck in the elderly. Laryngoscope 2003; 113: 368-372
12. Koch WM, Patel H, Brennan J, et al. Squamous cell carcinoma of the head and neck in the elderly. Arch Otolaryngol Head Neck Surg 1995; 121: 262-265
13. Hutchins LF, Unger JM, Crowley JJ, et al. Under-representation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med 1999; 341: 2061-2067
14. Lewis JH, Kilgore ML, Goldman DP, et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389
15. Sanabria A, Carvalho AL, Melo RL, et al. Predictive factors for complications in elderly patients who underwent head and neck oncologic surgery. Head Neck 2008; 30: 170-177
16. Ferrier MB, Spuesens EB, Le Cessie S, et al. Comorbidity as a major risk factor for mortality and complications in head and neck surgery. Arch Otolaryngol Head Neck Surg 2005; 131: 27-32
17. Derks W, de Leeuw RJ, Hordijk GJ. Elderly patients with head and neck cancer: The influence of comorbidity on choice of therapy, complication rate, and survival. Curr Opin Otolaryngol Head Neck Surg 2005; 13: 92-96
18. Do KA, Johnson MM, Lee JJ, et al. Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer 2004; 101: 2837-2842
19. Audisio RA, Bozzetti F, Gennari R, et al. The surgical management of elderly cancer patients: Recommendations of the SIOG surgical task force. Eur J Cancer 2004; 40: 926-938
20. McGuirt WF, Loevy S, McCabe BF, et al. The risks of major head and neck surgery in the aged population. Laryngoscope 1977; 87: 1378-1382
21. Barzan L, Veronesi A, Caruso G, et al. Head and neck cancer and ageing: A retrospective study in 438 patients. J Laryngol Otol 1990; 104: 634-640
22. Zabrodsky M, Calabrese L, Tosone A, et al. Major surgery in elderly head and neck cancer patients: Immediate and long-term surgical results and complication rates. Surg Oncol 2004; 13: 249-255
23. Shaari CM, Buchbinder D, Costantino PD, et al. Complications of microvascular head and neck surgery in the elderly. Arch Otolaryngol Head Neck Surg 1998; 124: 407-411
24. Sanabria A, Carvalho AL, Vartanian JG, et al. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007; 14: 1449-1457
25. Terhaard CH, Van der Schroeff MP, Van Schie K, et al. The prognostic role of comorbidity in salivary gland carcinoma. Cancer 2008; 113: 1572-1579
26. van der Schroeff MP, Derks W, Hordijk GJ, et al. The effect of age on survival and quality of life in elderly head and neck cancer patients: A long-term prospective study. Eur Arch Otorhinolaryngol 2007; 264: 415-422
27. Extermann M, Hurria A. Comprehensive geriatric assessment for older patients with cancer. J Clin Oncol 2007; 25: 1824-1831
28. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol 2002; 20: 494-502
29. Extermann M. Studies of comprehensive geriatric assessment in patients with cancer. Cancer Control 2003; 10: 463-468
30. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol 2005; 55: 241-252
31. Rodin MB, Mohile SG. A practical approach to geriatric assessment in oncology. J Clin Oncol 2007; 25: 1936-1944
32. Ashley J, Duggan M, Sutcliffe N. Speech, language, and swallowing disorders in the older adult. Clin Geriatr Med 2006; 22: 291-310
33. Pompei S, Tedesco M, Pozzi M, et al. Age as a risk factor in cervicofacial reconstruction. J Exp Clin Cancer Res 1999; 18: 209-212
34. Agrawal A, Moon J, Davis RK, et al. Transoral carbon dioxide laser supraglottic laryngectomy and irradiation in stage I, II, III squamous cell carcinoma of the supraglottic larynx: Report of the Southwest Oncology Group phase 2 trial S9709. Arch Otolaryngol Head Neck Surg 2007; 133: 1044-1050
35. Werner JA, Dunne AA, Folz BJ, et al. Transoral laser microsurgery in carcinomas of the oral cavity, pharynx, and larynx. Cancer Control 2002; 9: 379-386
36. Sesterhenn AM, Dü AA, Werner JA. Complications after CO2 laser surgery of laryngeal cancer in the elderly. Acta Otolaryngol 2006; 126: 530-535
37. Clayman G, Eicher SA, Sicard MW, et al. Surgical outcomes in head and neck cancer patients 80 years of age and older. Head Neck 1998; 20: 216-223
38. Italiano A, Ortholan C, Dassonville O, et al. Head and neck squamous cell carcinoma in patients aged > or = 80 years: patterns of care and survival. Cancer 2008; 113: 3160-3168
39. Smith GL, Smith BD, Buchholz TA, et al. Cerebrovascular disease risk in older head and neck cancer patients after radiotherapy. J Clin Oncol 2008; 26: 5119-5125
40. Fliser D. Assessment of renal function in elderly patients. Curr Opin Nephrol Hypertens 2008; 17: 604-608
41. Metges JP, Eschwege F, de Crevoisier R, et al. Radiotherapy in head and neck cancer in the elderly: A challenge. Crit Rev Oncol Hematol 2000; 34: 195-203
42. Schofield CP, Sykes AJ, Slevin NJ, et al. Radiotherapy for head and neck cancer in elderly patients. Radiother Oncol 2003; 69: 37-42
43. Pignon T, Horiot JC, Van Den Bogaert W, et al. No age limit for radical radiotherapy in head and neck tumours. Eur J Cancer 1996; 32A: 2075-2081
44. Lusinchi A, Bourhis J, Wibault P, et al. Radiation therapy for head and neck cancer in the elderly. Int J Radiat Oncol Biol Phys 1990; 18: 819-823
45. Zachariah B, Balducci L, Verkattaramanabalaji GV, et al. Radiotherapy for cancer patients aged 80 and older: A study of effectiveness and side effects. Int J Radiat Oncol Biol Phys 1997; 39: 1125-1129
46. Horiot JC. Radiation therapy and the geriatric oncology patient. J Clin Oncol 2007; 25: 1930-1935
47. Allal AS, Maire D, Becker M, et al. Feasibility and early results of accelerated radiotherapy for head and neck carcinoma in the elderly. Cancer 2000; 88: 648-652
48. Machtay M, Moughan J, Trotti A, et al. Factors associated with severe late toxicity after concurrent chemoradiation for locally advanced head and neck cancer: An RTOG analysis. J Clin Oncol 2008; 26: 3582-3589
49. Falandry C, Tarkouki K, Mornex F, et al. Is geriatric assessment adapted to radiotherapy? Cancer Radiother 2008; 12: 541-547
50. Moritz MW, Higgins RF, Jacobs JR. Duplex imaging and incidence of carotid radiation injury after high-dose radiotherapy for tumors of the head and neck. Arch Surg 1990; 125: 1181-1183
51. Dubec JJ, Munk PL, Tsang V, et al. Carotid artery stenosis in patients who have undergone radiation therapy for head and neck malignancy. Br J Radiol 1998; 71: 872-875
52. Brown PD, Foote RL, McLaughlin MP, et al. A historical prospective cohort study of carotid artery stenosis after radiotherapy for head and neck malignancies. Int J Radiat Oncol Biol Phys 2005; 63: 1361-1367
53. Flor N, Sardanelli F, Soldi S, et al. Unknown internal carotid artery atherosclerotic stenoses detected with biphasic multidetector computed tomography for head and neck cancer. Eur Radiol 2006; 16: 866-871
54. Duffy SA, Ronis DL, Valenstein M, et al. A tailored smoking, alcohol, and depression intervention for head and neck cancer patients. Cancer Epidemiol Biomarkers Prev 2006; 15: 2203-2208
55. Nishimura G, Tsukuda M, Horiuchi C, et al. Decrease of creatinine clearance rate with aging in patients with head and neck cancer in Japan. Int J Clin Oncol 2007; 12: 120-124
56. Lee M. Age-related changes in gastric blood flow in rats. Gerontology 1996; 42: 289-293
57. Kumar A, Soares HP, Balducci L, et al. Treatment tolerance and efficacy in geriatric oncology: A systematic review of phase III randomized trials conducted by five National Cancer Institute-sponsored cooperative groups. J Clin Oncol 2007; 25: 1272-1276
58. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology Chemotherapy Taskforce: Evaluation of chemotherapy in older patients - an analysis of the medical literature. J Clin Oncol 2007; 25: 1832-1843
59. Wildiers H. Mastering chemotherapy dose reduction in elderly cancer patients. Eur J Cancer 2007; 43: 2235-2241
60. Kish JA, Weaver A, Jacobs J, et al. Cisplatin and 5-fluoruracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819-1824
61. Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 1994; 21: 311-319
62. Argiris A, Li Y, Murphy BA, et al. Outcome of elderly patients with recurrent or metastatic head and neck cancer treated with cisplatin-based chemotherapy. J Clin Oncol 2004; 22: 262-268
63. Forastiere AA, Metch B, Schuller DE, et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-1251
64. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol 2006; 24: 1846-1851
65. Vermorken JB, Remenar E, Van Herpen C, et al. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 2007; 357: 1695-1704
66. Hurria A, Fleming MT, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006; 12: 6100-6105
67. Shin HJ, Chung JS, Choi YJ, et al. Neoadjuvant docetaxel and cisplatin chemotherapy followed by local irradiation is highly active on locoregionally advanced squamous cell carcinoma of the head and neck. J Laryngol Otol 2008; 122: 722-727
68. Hensley ML, Hagerty KL, Kewalramani T, et al. American Society of Clinical Oncology 2008 Clinical Practice Guideline Update: Use of chemotherapy and radiation therapy protectants. J Clin Oncol 2009; 27: 127-145
69. Rizzo JD, Somerfield MR, Hagerty KL, et al. Use of epoietin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update [published erratum appears in J Clin Oncol 2008; 26: 1192]. J Clin Oncol 2008; 26: 132-149
70. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 update of recommendations for the use of white blood cell growth factors: An evidence-based clinical practice guideline. J Clin Oncol 2006; 24: 3187-3205
71. Vermorken J, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008; 359: 1116-1127
72. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5568-5577
73. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005; 23: 5578-5587
74. Vermorken JB, Trigo J, Hitt R, et al. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy. J Clin Oncol 2007; 25: 2171-2177
75. Burtness B, Goldwasser MA, Flood W, et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: An Eastern Cooperative Oncology Group study [published erratum appears in J Clin Oncol 2006; 24: 724]. J Clin Oncol 2005; 23: 8646-8654
76. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-578
77. Stewart JS, Cohen EE, Licitra L, et al. Phase III study of gefitinib 250 compared with intravenous methotrexate for recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2009; 27: 1864-1871
78. Soulieres D, Senzer NN, Vokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol 2004; 22: 77-85
79. Siu LL, Soulieres D, Chen EX, et al. Phase I/II trial of erlotinib and cisplatin in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: A Princess Margaret Hospital phase II Consortium and National Cancer Institute of Canada Clinical Trials Group Study. J Clin Oncol 2007; 25: 2178-2183
80. Argiris A, Ghebremichael M, Gilbert J, et al. A phase III randomized, placebo-controlled trial of docetaxel with or without gefitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: A trial of the Eastern Cooperative Oncology Group [abstract]. J Clin Oncol 2009; 27 (15S): 303s
81. Burtness BA, Manola J, Axelrod R, et al. A randomized phase II study of ixabepilone (BMS-247550) given daily x 5 days every 3 weeks or weekly in patients with metastatic or recurrent squamous cell cancer of the head and neck: An Eastern Cooperative Oncology Group study. Ann Oncol 2008; 19: 977-983
82. Bernier J. Current state-of-the-art for concurrent chemoradiation. Semin Radiat Oncol 2009; 19: 3-10
83. Ampil FL, Mills GM, Stucker FJ, et al. Radical combined treatment of locally extensive head and neck cancer in the elderly. Am J Otolaryngol 2001; 22: 65-69
84. Airoldi M, Cortesina G, Giordano C, et al. Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 161-166
85. Pignon JP, le Ma?tre A, Bourhis J. Meta-analyses of chemotherapy in head and neck cancer (MACH-NC): An update. Int J Radiat Oncol Biol Phys 2007; 69 (2 Suppl.): S112-S124
86. Bourhis J, Le Matre A, Pignon J, et al. Impact of age on treatment effect in locally advanced head and neck cancer (HNC): Two individual patient data meta-analyses [abstract]. J Clin Oncol 2006; 24 (18S): 5501
87. Kodaira T, Fuwa N, Furutani K, et al. Phase I trial of weekly docetaxel and concurrent radiotherapy for head and neck cancer in elderly patients or patients with complications. Jpn J Clin Oncol 2005; 35: 173-176
88. Robbins KT, Kumar P, Harris J, et al. Supradose intraarterial cisplatin and concurrent radiation therapy for the treatment of stage IV head and neck squamous cell carcinoma is feasible and efficacious in a multi-institutional setting: Results of Radiation Therapy Oncology Group Trial 9615. J Clin Oncol 2005; 23: 1447-1454
89. Hao D, Lau HY, Eliasziw M, et al. A comprehensive evaluation of the prognostic value of ERCC1 protein expression, mRNA and genotype in locally advanced squamous cell carcinoma of the head and neck [abstract]. J Clin Oncol 2008; 26 (15S): 318s
90. Fakhry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst 2008; 100: 261-269